Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study
BioMed Research International2018Vol. 2018, pp. 1–6
Citations Over TimeTop 12% of 2018 papers
Korbinian Lackermair, Christoph Schuhmann, Michaela Kubieniec, Lisa Riesinger, Ina Klier, Thomas J. Stocker, Stefan Kääb, Heidi Estner, Stephanie Fichtner
Abstract
In our cohort, no SCD was prevented by WCD therapy. In contrast, in this preliminary study quality of life was reduced. Thus, careful recommendation of WCD therapy for high risk patients should be considered.
Related Papers
- Prescription-writing errors and markers: the value of knowing the diagnosis.(1993)
- Comments and analysis of outpatient prescriptions(2012)
- Theory of main prescription matched to main disease(2014)
- → Assessment of prescribing in under-five paediatric outpatients in Nigeria: an application of the POPI (Pediatrics: Omission of Prescription and Inappropriate Prescription) tool(2023)